Yuan Chen

List of Publications by Year
in descending order

58 papers	2,054 citations	394421 19 h-index	254184 43 g-index
60 all docs	60 docs citations	60 times ranked	3572 citing authors

#	ARTICLE	IF	CITATIONS
1	Knowledge, Practices, and Perceived Barriers in Cancer Pain Management at Oncology Units: A Cross-Sectional Survey of Medical Staff in China. Journal of Pain Research, 2022, Volume 15, 159-169.	2.0	4
2	Impact of marital status on survival in patients with stage 1A NSCLC. Aging, 2022, 14, 770-779.	3.1	6
3	SIX1 Predicts Poor Prognosis and Facilitates the Progression of Non-small Lung Cancer via Activating the Notch Signaling Pathway. Journal of Cancer, 2022, 13, 527-540.	2.5	7
4	The roles of CC chemokines in response to radiation. Radiation Oncology, 2022, 17, 63.	2.7	21
5	Long noncoding RNA PVT1 regulates the proliferation and apoptosis of ARPE-19 cells *in vitro* via the miR-1301-3p/KLF7 axis. Cell Cycle, 2022, 21, 1590-1598.	2.6	4
6	Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf--lammasome Activation, and Reversing Gut Microbiota Disorder. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-17.	4.0	3
7	A real-world study update: Efficacy and safety of anlotinib for advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, e21106-e21106.	1.6	0
8	Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.. Journal of Clinical Oncology, 2022, 40, 9114-9114.	1.6	1
9	Lower lobe origin is related to unfavorable outcomes in patients with stage I–III lung cancer treated with radical chemoradiotherapy. Tumori, 2021, 107, 400-406.	1.1	1
10	An online tool for predicting the prognosis of cancer patients with SARS-CoV-2 infection: a multi-center study. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1247-1257.	2.5	8
11	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. Clinical Cancer Research, 2021, 27, 1296-1304.	7.0	79
12	Comparison of the oncological, perioperative and functional outcomes of partial nephrectomy versus radical nephrectomy for clinical T1b renal cell carcinoma: A systematic review and meta-analysis of retrospective studies. Asian Journal of Urology, 2021, 8, 117-125.	1.2	10
13	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. Journal of Thoracic Oncology, 2021, 16, 827-839.	1.1	24
14	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial. Cancer Communications, 2021, 41, 889-903.	9.2	16
15	Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring *MET exon 14* skipping alterations (*METex14*). Cancer Research, 2021, 81, CT158-CT158.	0.9	4
16	The Experiences of Community‐dwelling older adults during the COVID‐19 Lockdown in Wuhan: A qualitative study. Journal of Advanced Nursing, 2021, 77, 4805-4814.	3.3	17
17	Characteristics of immune and inflammatory responses among different age groups of pediatric patients with COVID-19 in China. World Journal of Pediatrics, 2021, 17, 375-384.	1.8	10
18	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	2.8	12

#	Article	IF	Citations
19	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respiratory Medicine,the, 2021, 9, 1154-1164.	10.7	107
20	Treatment beyond progression with chemo-immunotherapy in an advanced esophageal squamous cell carcinoma patient: a case report. Translational Cancer Research, 2021, 10, 4973-4978.	1.0	1
21	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 45-53.	10.7	105
22	A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study. , 2020, 8, e001314.		26
23	Discussion of Advance Care Planning on end of life decisions with lung cancer patients in Wuhan China: Attitude, Timing, and Future Directions. Internal Medicine Journal, 2020, , .	0.8	5
24	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. Translational Lung Cancer Research, 2020, 9, 269-279.	2.8	64
25	PDPN is a prognostic biomarker and correlated with immune infiltrating in gastric cancer. Medicine (United States), 2020, 99, e19957.	1.0	17
26	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer â€" The FALUCA study. Lung Cancer, 2020, 146, 252-262.	2.0	12
27	Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype. Experimental Cell Research, 2020, 391, 111956.	2.6	61
28	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).. Journal of Clinical Oncology, 2020, 38, 9519-9519.	1.6	50
29	mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelialâ€"mesenchymal transition. Acta Pharmacologica Sinica, 2019, 40, 1085-1094.	6.1	14
30	Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Translational Lung Cancer Research, 2019, 8, 1016-1028.	2.8	16
31	Estrogen receptor Î² promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. Oncogene, 2019, 38, 1225-1238.	5.9	89
32	The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin. Supportive Care in Cancer, 2018, 26, 2763-2767.	2.2	9
33	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung â€" A Multicenter, Open-label, Randomized, Phase III Trial. Journal of Thoracic Oncology, 2018, 13, 1743-1749.	1.1	13
34	Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis. BMC Cancer, 2018, 18, 808.	2.6	10
35	Leinal polypeptide promotes NK cells to suppress PCa survival inÃ¯Â¿Â½vitro. Oncology Letters, 2018, 16, 425-430.	1.8	1
36	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	2.8	7

#	Article	IF	Citations
37	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial.. Journal of Clinical Oncology, 2018, 36, 9077-9077.	1.6	1
38	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. Cancer Letters, 2017, 403, 186-194.	7.2	27
39	Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. Oncotarget, 2017, 8, 62330-62338.	1.8	5
40	Detect T790M in cell free tumor DNA of Chinese advanced non-small cell lung cancer adenocarcinoma patients by different platforms and evaluate clinical outcomes of T790M positive patients with osimertinib monotherapy.. Journal of Clinical Oncology, 2017, 35, TPS9104-TPS9104.	1.6	0
41	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 83.	17.0	45
42	miR-34C Disrupts the Stemness of Purified CD133 + Prostatic Cancer Stem Cells. Urology, 2016, 96, 177.e1-177.e9.	1.0	6
43	The CXCL8-CXCR1/2 pathways in cancer. Cytokine and Growth Factor Reviews, 2016, 31, 61-71.	7.2	471
44	Emerging roles of Nrf2 signal in non-small cell lung cancer. Journal of Hematology and Oncology, 2016, 9, 14.	17.0	50
45	Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling. Clinical Cancer Research, 2016, 22, 1531-1544.	7.0	24
46	Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. Oncotarget, 2016, 7, 7842-7855.	1.8	72
47	Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer. OncoTargets and Therapy, 2015, 8, 2209.	2.0	11
48	The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. OncoTargets and Therapy, 2015, 8, 3575.	2.0	20
49	Association of single nucleotide polymorphisms of ABCB1, OPRM1 and COMT with pain perception in cancer patients. Journal of Huazhong University of Science and Technology [Medical Sciences], 2015, 35, 752-758.	1.0	14
50	Prior Study of Cross-Cultural Validation of McGill Quality-of-Life Questionnaire in Mainland Mandarin Chinese Patients With Cancer. American Journal of Hospice and Palliative Medicine, 2015, 32, 709-714.	1.4	10
51	Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Scientific Reports, 2015, 5, 10338.	3.3	96
52	Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. PLoS ONE, 2015, 10, e0131689.	2.5	75
53	DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget, 2015, 6, 5877-5888.	1.8	40
54	Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget, 2015, 6, 31203-31215.	1.8	37

#	Article	IF	Citations
55	Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. Journal of Hematology and Oncology, 2014, 7, 87.	17.0	196
56	In Vitro Evaluation of the Inhibitory Potential of Pharmaceutical Excipients on Human Carboxylesterase 1A and 2. PLoS ONE, 2014, 9, e93819.	2.5	18
57	Preliminary results of gentamycin combined with sodium bicarbonate for prevention of irinotecan-induced diarrhea. Frontiers of Medicine in China, 2009, 3, 470-474.	0.1	1
58	CYFRA 21-1 as an early predictor of first line chemotherapy response in advanced non small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2007, 6, P250-P253.	0.1	1